Leqembi™ (lecanemab-irmb) – FDA Advisory Committee update
June 9, 2023 - The FDA convened a Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) meeting to discuss Eisai/Biogen’s Leqembi (lecanemab) for the treatment of early Alzheimer's disease.
Download PDF
